Nevro (NVRO) Misses Q4 EPS by 11c, Revenues Beat; Offers FY19 Revenue Views Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Nevro Reports Fourth Quarter and Full Year 2018 Financial Results
February 21, 2019 4:10 PM ESTREDWOOD CITY, Calif., Feb. 21, 2019 /PRNewswire/ --Â Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the fourth quarter and full year ended December 31, 2018.
2018 Accomplishments and Recent Highlights
Hired Michael Carter as Vice President, Global Sales to lead worldwide sales organization Launched Senza II: a smaller-footprint, advanced battery system with 10+ year life, and subsequently received FDA Approval for Conditional Full Body MRI Published a global registry of long-term... More